Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24688181 | 0.94 | MAOA (0.64) | MAOAMAOBALDH1A1MAPK1MTNR1A | |
| SCHEMBL1539929 | 0.94 | MAOA (0.64) | MAOAMAOBALDH1A1MAPK1MTNR1A | |
| Dimethylamine SCHEMBL554509 | 0.82 | MAOA (0.55) | MAOAMAOBALDH1A1MAPK1MTNR1A | |
| Tartaric Acid SCHEMBL30165591 | 0.82 | MAOA (0.50) | MAOAMAOBMTNR1AMTNR1BSLC6A4 | |
| SCHEMBL3441777 | 0.76 | MAOA (0.61) | MAOAMAOBALDH1A1MAPK1MTNR1A | |
| SCHEMBL26648827 | 0.76 | MAOA (0.71) | MAOAMAOBALDH1A1MAPK1MTNR1A | |
| SCHEMBL1540101 | 0.75 | MAOA (0.55) | MAOAMAOBALDH1A1MAPK1MTNR1A | |
| SCHEMBL7751748 | 0.75 | MAOA (0.46) | MAOAMAOBALDH1A1SLC6A4 | |
| SCHEMBL4905285 | 0.75 | MAOA (0.50) | MAOAMAOBALDH1A1MAPK1MTNR1A | |
| SCHEMBL8208513 | 0.75 | MAOA (0.50) | MAOAMAOBALDH1A1MAPK1MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035134-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035134-A1 | CHEMICAL COMPOUNDS | BCL2, BCL2L1, BAX | MAOA 1944/4885MAOB 811/4885ALDH1A1 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.